Indivior PLC (LON:INDV – Get Free Report) shares dropped 16% during mid-day trading on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 729.50 ($9.22). Approximately 78,684,203 shares traded hands during trading, an increase of 2,668% from the average daily volume of 2,842,694 shares. The stock had previously closed at GBX 868 ($10.97).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reiterated a “buy” rating and set a GBX 1,800 ($22.74) price target on shares of Indivior in a research note on Tuesday, December 17th.
Read Our Latest Analysis on INDV
Indivior Stock Performance
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- Stock Dividend Cuts Happen Are You Ready?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- How to Calculate Inflation Rate
- DuPont’s Electronics Spinoff: The Start of Something Big
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.